Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a regenerative medicine company focused on stem cell-based therapies and products, and its news flow reflects activity across clinical development, intellectual property, commercialization, and capital markets. The company develops therapeutic products using adult stem cell protocols, with core programs in disc and spine disease, metabolic disorders, and a commercial BioCosmeceutical platform.
News about BRTX often centers on its disc/spine program (brtxDISC™) and lead cell therapy candidate BRTX-100. Recent announcements include Fast Track designation from the U.S. Food and Drug Administration (FDA) for the BRTX-100 Phase 2 trial in chronic lumbar disc disease and the granting of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application approval pathway. Updates also cover blinded Phase 2 clinical data presented at scientific meetings and the status of enrollment and trial progress.
Another key news theme is the ThermoStem® metabolic program, where BioRestorative has reported milestones such as a Notice of Allowance from the Japanese Patent Office for its allogeneic, off-the-shelf brown adipose-derived stem cell technology designed to treat obesity and metabolic disorders. Press releases describe how this intellectual property strengthens protection for cell-based approaches that aim to generate brown adipose tissue and utilize exosomes secreted by brown adipose-derived stem cells.
Investors following BRTX news will also see coverage of the company’s BioCosmeceutical platform, including commercial developments for its cell-based secretome serum, as well as corporate events such as equity financings, stock repurchase authorizations, conference presentations, and quarterly financial results. This page aggregates these updates so readers can track BioRestorative’s clinical, commercial, and financial disclosures in one place.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has scheduled the release of its 2024 financial results for Thursday, March 27, 2025, after market close. The company's management team will conduct a conference call following the announcement to discuss the financial performance and provide updates on business operations.
Investors and interested parties can access the live broadcast and archived recording of the conference call through the company's website at biorestorative.com/investor-relations under the Events section.
BioRestorative Therapies (NASDAQ:BRTX) has received FDA clearance for its Investigational New Drug (IND) application for BRTX-100, marking a significant advancement in stem cell-based therapies. The treatment, designed to target areas with blood flow, will be evaluated for chronic cervical discogenic pain (cCDP) in a Phase 2 trial.
BRTX-100 represents the first and only stem cell product candidate cleared for evaluation in cervical degenerative disc disease. This expansion builds upon the company's existing FDA Fast Track-designated program for chronic lumbar disc disease (cLDD). The upcoming Phase 2 study will be conducted as a double-blind, sham-controlled, randomized trial to assess safety and preliminary efficacy of intradiscal BRTX-100 injections.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has rescheduled its webcasted conference call to discuss pipeline updates. The call will now take place on Thursday, February 27, 2025, at 10:30am EST.
Participants can join via telephone by dialing 888-506-0062 (US) or 973-528-0011 (International) using access code 440089. The conference call will be broadcast live and archived in the Investor Relations section of the company's website at biorestorative.com.
BioRestorative Therapies (NASDAQ:BRTX) has announced it will provide a positive clinical pipeline update before market open on Thursday, February 27, 2025. The regenerative medicine company, which focuses on stem cell-based therapies, will share what CEO Lance Alstodt describes as "meaningful key developments" regarding their clinical pipeline.
Alstodt expressed enthusiasm about the upcoming announcement, noting that it reflects "the very solid work of our scientific team over the last several years come to fruition" and mentioned additional positive events related to BRTX-100, one of the company's products.
The company will host a webcasted conference call at 8:00am EST on February 27, 2025, accessible by dialing 888-506-0062 (US) or 973-528-0011 (International) with participant access code 440089. The call will also be broadcast live and archived on the Investor section of BioRestorative's website.
BioRestorative Therapies (NASDAQ:BRTX) has received FDA Fast Track designation for its BRTX-100 program targeting chronic lumbar disc disease (cLDD). This designation highlights the significant unmet medical need for alternatives to opioids and surgical interventions in cLDD treatment.
The Fast Track status was granted based on positive preliminary Phase 2 safety and efficacy data reported to date. This designation may accelerate the development process, potentially leading to Priority Review and expedited Biologics License Application (BLA) approval for BRTX-100.
The company's stem cell therapy aims to provide effective pain relief and functional improvement for millions of cLDD patients who have experienced ineffective conservative non-surgical approaches or failed surgical interventions.
BioRestorative Therapies (NASDAQ:BRTX) presented new blinded preliminary data from its Phase 2 clinical trial of BRTX-100 at the Orthopaedic Research Society annual meeting. The data, now covering 15 patients with chronic lumbar disc disease (cLDD), showed significant improvements:
- Pain reduction (VAS): 71.20% at 26 weeks and 73.58% at 52 weeks
- Function improvement (ODI): 69.04% at 26 weeks and 65.16% at 52 weeks
- No serious adverse events reported
- First-time MRI analysis showed potential disc microenvironment remodeling
These results significantly exceed the FDA's minimum threshold requirement of 30% improvement. The ongoing Phase 2 trial will enroll up to 99 subjects across 16 U.S. clinical sites, randomized 2:1 to receive either BRTX-100 or placebo.
BioRestorative Therapies (NASDAQ:BRTX) has received a Notice of Allowance from the European Patent Office for a new patent application covering their ThermoStem® metabolic disease platform. The patent (No. 20798130.9) protects the method of creating non-naturally occurring three-dimensional brown adipose derived stem cell aggregates and is expected to provide protection until April 29, 2040.
The company is developing an exosome-based biologic program targeting obesity and plans to initiate the FDA process by filing a Drug Master File. BioRestorative is currently in discussions with an unnamed commercial stage regenerative medicine company regarding potential licensing of their ThermoStem® metabolic intellectual property, though no agreement has been finalized.
BioRestorative Therapies announced promising preliminary data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease. The blinded data from the first 10 patients showed significant improvements in pain reduction and function increase. At 26 weeks, 70% of subjects reported >30% improvement in both pain (VAS) and function (ODI). At 52 weeks, 100% of subjects (n=4) showed >30% improvement in both metrics. No serious adverse events were reported, and there was no dose limiting toxicity at 26-52 weeks. The ongoing trial will enroll up to 99 subjects across 16 U.S. clinical sites, randomized 2:1 for BRTX-100 or placebo.
BioRestorative Therapies (NASDAQ:BRTX) reported its Q3 2024 financial results, showing improved operational performance with a reduced loss from operations of $2.3 million, down 26% year-over-year. The company generated $230,700 in product revenue from its supply agreement with Cartessa Aesthetics. Key developments include receiving a provisional license from NYSDOH for allogeneic tissue processing and advancing its BRTX-100 Phase 2 clinical trial for chronic lumbar disc disease. The company maintains a strong financial position with $13.1 million in cash and investments, with no outstanding debt as of September 30, 2024.
BioRestorative Therapies (NASDAQ:BRTX) announces upcoming presentation of new preliminary data from its Phase 2 clinical trial of BRTX-100 at the ORS PSRS 7th International Spine Research Symposium. The presentation will include 26-52 week blinded safety and efficacy data from a larger patient group than previously reported in their chronic lumbar disc disease (cLDD) study. The Phase 2 trial is a randomized, double-blinded study enrolling up to 99 subjects across 16 U.S. clinical sites. The company will also release Q3 2024 financial results and host a conference call on November 13, 2024.